CAI
Caris Life Sciences, Inc.Company Information
- Company Name
- Caris Life Sciences, Inc.
- CIK
- CIK0002019410
- Category
- Non-accelerated filer<br>Emerging growth company
- Ticker: Exchange
- CAI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8071
- SIC Description
- Services-Medical Laboratories
- Ticker
- CAI
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-11
- Last sale
- 2025-12-11
- Shares purchased (TTM)
- 73,134
- Shares sold (TTM)
- 62,250
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 141,225,999
- Shares outstanding
- 282,562,013
- Ownership
- 49.98%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 55.81%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred Stock | - | - | 0 | 0 | 0 | ||||||
| Series B Preferred Stock | - | - | 0 | 0 | 0 | ||||||
| Series C Preferred Stock | - | - | 0 | 0 | 0 | ||||||
| Series D Preferred Stock | - | - | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | 787 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | 751 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | 751 | ||||||
| Temporary Equity Liquidation Preference | - | - | - | - | 1,946 | ||||||
Assets Current | |||||||||||
| Marketable Securities Current | 102 | 2 | 2 | 2 | 2 | ||||||
| Accounts Receivable Net Current | 117 | 91 | 112 | 27 | 51 | ||||||
| Supplies | 124 | 76 | 64 | 49 | 41 | ||||||
| Prepaid Expense And Other Assets Current | 24 | 24 | 22 | 21 | 19 | ||||||
| Assets Current | 1,058 | 1,014 | 998 | 854 | 833 | ||||||
| Property Plant And Equipment Net | 96 | 83 | 63 | 64 | 61 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | - | - | 63 | - | - | ||||||
| Goodwill | 19 | 19 | 19 | 19 | 19 | ||||||
| Other Assets Noncurrent | 57 | 46 | 45 | 47 | 41 | ||||||
| Assets | 1,230 | 1,162 | 1,126 | 985 | 955 | ||||||
Liabilities Current | |||||||||||
| Accounts Payable Current | 86 | 70 | 39 | 29 | 29 | ||||||
| Accrued Liabilities Current | 105 | 74 | 88 | 57 | 61 | ||||||
| Long Term Debt Current | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 191 | 144 | 127 | 86 | 90 | ||||||
| Long Term Debt Noncurrent | 393 | 381 | 379 | 376 | 374 | ||||||
| Other Liabilities Noncurrent | 53 | 44 | 42 | 44 | 38 | ||||||
| Liabilities | 638 | 569 | 548 | 506 | 502 | ||||||
Equity | |||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Value | 0 | -17 | -17 | -17 | -17 | ||||||
| Additional Paid In Capital | 3,141 | 3,158 | 3,142 | 3,125 | 3,124 | ||||||
Temporary Equity Number Of Shares Redemption Value And Other Disclosures | |||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | 0 | 2,446 | ||||||
| Retained Earnings Accumulated Deficit | -2,550 | -2,549 | -2,549 | -2,631 | -2,655 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | 1 | 1 | 1 | ||||||
| Stockholders Equity | 592 | 593 | 577 | 478 | 453 | ||||||
| Liabilities And Stockholders Equity | 1,230 | 1,162 | 1,126 | 985 | 955 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 2,800 | 2,800 | 2,800 | 2,800 | 2,800 | ||||||
| Common Stock Shares Issued | 283 | 284 | 284 | 284 | 283 | ||||||
| Shares Outstanding | 283 | 283 | 283 | 282 | 281 | ||||||
| Common Stock Other Shares Outstanding | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Shares | 0 | 2 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCaris Life Sciences, Inc. (CAI) — SEC Financial Statements & Analysis
Caris Life Sciences, Inc. (CAI) is a services-medical laboratories company, incorporated in TX. Caris Life Sciences, Inc. trades on Nasdaq as: CAI. Caris Life Sciences, Inc. (CAI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Caris Life Sciences, Inc. carries a market cap of $5.04B, a P/E ratio of -10.79x, a P/B ratio of 8.52x, a P/S ratio of 4.54x, an enterprise value of $5.43B, and an EV/EBITDA multiple of 44.15x. On profitability, it posts a gross margin of 68.37%, an operating margin of 8.58%, a net margin of -42.08%, a Return on Equity (ROE) of -89.47%, a Return on Assets (ROA) of -42.78%, and a Return on Invested Capital (ROIC) of 10.04%. Per share, it reports EPS of $-1.65, diluted EPS of $-1.65, free cash flow per share of $0.40, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 5.53x, a quick ratio of 5.40x, working capital of $866.39M, a debt-to-equity ratio of 1.08x, a debt ratio of 0.52, an interest coverage ratio of 1.60x, free cash flow of $113.61M (TTM), and net debt of $393.15M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.04B
- P/E TTM
- -10.79x
- EPS TTM
- $-1.65
- P/B TTM
- 8.52x
- ROE TTM
- -89.47%
- ROA TTM
- -42.78%
- Debt To Equity
- 1.08x
- Free Cash Flow TTM
- $113.61M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Caris Life Sciences, Inc. in?
Caris Life Sciences, Inc. (CAI) operates in the Services-Medical Laboratories industry.
What exchange does CAI trade on?
Caris Life Sciences, Inc. (CAI) trades on the Nasdaq.
Where is Caris Life Sciences, Inc. incorporated?
Caris Life Sciences, Inc. is incorporated in TX.
When was Caris Life Sciences, Inc. (CAI)'s most recent SEC filing?
Caris Life Sciences, Inc. (CAI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is CAI's market cap?
Caris Life Sciences, Inc. (CAI) has a market capitalization of $5.04B as of 2026-06-30.
What is CAI's EPS (earnings per share)?
Caris Life Sciences, Inc. (CAI)'s trailing twelve month EPS is $-1.65 as of 2026-06-30.
What is CAI's ROE (return on equity)?
Caris Life Sciences, Inc. (CAI)'s trailing twelve month Return on Equity (ROE) is -89.47% as of 2026-06-30.
What is CAI's ROA (return on assets)?
Caris Life Sciences, Inc. (CAI)'s trailing twelve month Return on Assets (ROA) is -42.78% as of 2026-06-30.
What is CAI's ROIC (return on invested capital)?
Caris Life Sciences, Inc. (CAI)'s trailing twelve month Return on Invested Capital (ROIC) is 10.04% as of 2026-06-30.
What is CAI's EV/EBITDA?
Caris Life Sciences, Inc. (CAI)'s trailing twelve month EV/EBITDA is 44.15x as of 2026-06-30.